2024 Cilt 50 Sayı 2

Permanent URI for this collectionhttps://hdl.handle.net/11452/48919

Browse

Browsing by BUU Author "ASLAN, MÜNİR KİPER"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Additional daily ıntramuscular progesterone for luteal phase support does not ımprove live birth rates of programmed frozen-thawed embryo transfer cycles
    (Bursa Uludağ Üniversitesi, 2024-06-01) Aslan, Kiper; Kasapoğlu, Işıl; Akkok, Tuğba; Çakır, Cihan; Avcı, Berrin; Uncu, Gürkan; ASLAN, MÜNİR KİPER; KASAPOĞLU, IŞIL; AKKÖK, TUĞBA; ÇAKIR, CİHAN; AVCI, BERRİN; UNCU, GÜRKAN
    This retrospective cohort study aims to investigate whether additional daily intramuscular progesterone (IMP) for luteal phase support improves live birth rates of programmed frozen-thawed embryo transfer (FET) cycles. The study was conducted at a tertiary level university hospital assisted reproductive technology (ART) center between January 2014 and Jan 2021. Six hundred four infertile patients with single-day 5-6 frozen-thawed blastocyst embryo transfer were enrolled in the study. All patients received either 8% micronized vaginal gel or vaginal progesterone capsules for luteal phase support. Intramuscular progesterone was added to vaginal progesterone depending on the in vitro fertilization (IVF) specialist’s choice. Luteal phase support (LPS) was started 6 days before transfer in frozen-thawed cycles and continued until the end of the first trimester. Cycles were compared depending on vaginal progesterone types (8% gel vs. capsule) and the presence of intramuscular progesterone. The primary outcome was the live birth rate. A total of 604 FET cycles were enrolled. Using 8% micronized progesterone or progesterone capsules did not change the live birth rates (24% vs. 25.9%). As the main result, intramuscular progesterone support with vaginal progesterone compared with only vaginal progesterone did not improve the live birth results (22% vs. 24%). In conclusion, this study demonstrated that routine IMP progesterone given in combination with vaginal progesterone does not improve ART outcomes. This combination may be beneficial in a selective population with a monitored luteal phase. Using any form of vaginal progesterone alone is adequate for LPS.
  • Thumbnail Image
    Publication
    The effect of the gonadotropin dose increment during controlled ovarian hyperstimulation on live birth rates of POSEIDON group 3-4 patients
    (Bursa Uludağ Üniversitesi, 2024-06-12) Aslan, Kiper; Kasapoğlu, Işıl; Mesut, Çağatay; Gürbüz, Tansu Bahar; Çakır, Cihan; Avcı, Berrin; Uncu, Gürkan; ASLAN, MÜNİR KİPER; KASAPOĞLU, IŞIL; MESUT, ÖMER ÇAĞATAY; GÜRBÜZ, TANSU BAHAR; ÇAKIR, CİHAN; AVCI, BERRİN; UNCU, GÜRKAN
    This retrospective study seeks to explore whether modifying the gonadotropin dose in cases of poor ovarian response during controlled ovarian hyperstimulation contributes to improved live birth rates in Poseidon Group 3-4 patients. The study took place at a tertiary level university. The electronic database spanning 2012-2021 was scrutinized to identify patients with diminished ovarian reserve (DOR) who underwent intra-cytoplasmic sperm injection – embryo transfer (ICSI-ET). Diminished ovarian reserve was determined using the POSEIDON criteria. Patients were categorized into two groups based on whether dose adjustment was implemented during the initial ultrasound assessment in controlled ovarian hyperstimulation (COH). There were 188 patients in the dose adjustment (DA) group and 310 patients in the fixed-dose (FD) group. The demographic parameters were similar between the groups. The started gonadotropin dose was similar in both groups (300 IU). The median dose adjustment on the first control was +75 IU in the DA group. The follicle output rates, follicle to oocyte indexes, and the embryology parameters were comparable between the groups. The positive pregnancy rate was 19.7% (36/188) in the DA group vs. 19.1% (61/310) in the FD Group (p=0.4). The primary outcome of the study; live birth rates were 12% in the DA group vs. 9% in the FD group, and the results were statistically similar (p=0.3). Our research revealed that adjusting the gonadotropin dose in cases of inadequate ovarian response during COH results in comparable live birth rates to those observed in the fixed-dose group. For patients exhibiting an inadequate response, dose adjustment may be deemed necessary.